Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
FLT3
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN15695 | UNC2025 | 1429881-91-3 | UNC2025 is an inhibitor of Mer and Flt3 with IC50 of 08 nM and 074 nM respectively |
| CSN19156 | UNC2025 HCl | 2070015-17-5 | UNC2025 HCl is a potent and orally bioavailable MerFlt3 dual inhibitor with IC50 of 08074 nM for MerFlt3 |
| CSN13941 | TCS 359 | 301305-73-7 | TCS 359 a 2-acylaminothiophene-3-carboxamide is a potent inhibitor of FLT3 with IC50 of 42 nM |
| CSN12033 | Tandutinib | 387867-13-2 | Tandutinib is an antagonist of FLT3 with IC50 of 0.22 M and can also inhibit PDGFR and c-Kit thereby inhibiting cellular proliferation and inducing apoptosis. |
| CSN20533 | SU-5614 | 1055412-47-9 | SU-5614 is an inhibitor of FLT3 In BaF3 and AML cell lines expressing a constitutively activated FLT3 SU-5614 exhibits significant cell growth inhibition and cell cycle arrest |
| CSN13100 | Quizartinib | 950769-58-1 | Quizartinib is a second-generation FLT3 inhibitor for Flt3 ITDWT with IC50 of 11 nM42 nM being 10-fold selective for Flt3 than KIT PDGFR PDGFR RET and CSF-1R |
| CSN17304 | KW-2449 | 1000669-72-6 | KW-2449 is a multiple-targeted inhibitor mostly for Flt3 with IC50 of 66 nM modestly potent to FGFR1 Bcr-Abl and Aurora A and showing little effect on PDGFR IGF-1R EGFR |
| CSN13926 | Gilteritinib | 1254053-43-4 | Gilteritinib is a potent FLT3AXL inhibitor with IC50 of 029 nM 1 nM respectively and shows potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations |
| CSN13783 | G-749 | 1457983-28-6 | G-749 is a FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 04063575 nM for Wt Flt3D835YMV4-11Molm-14 respectively |
| CSN16867 | FLT3-IN-2 | 923562-23-6 | FLT3-IN-2 is a FLT3 inhibitor with IC50 of 1 M |
| CSN21240 | FLT3-IN-1 Succinate | 1702864-11-6 | FLT3-IN-1 Succinate is a potent FLT3 inhibitor extracted from patent WO2015056683A1 compound example A |
| CSN21235 | FLT3-IN-1 | 1472797-69-5 | FLT3-IN-1 is a potent FLT3 inhibitor extracted from patent WO2015056683A1 compound example A |
| CSN16265 | SKLB4771 | 1370256-78-2 | FLT3-IN-1 is a potent and selective Flt3 inhibitor with IC50 of 10 nM and against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM |
| CSN20591 | Famitinib | 1044040-56-3 | Famitinib a structural analogue of sunitinib is a multi-targeted receptor tyrosine kinase inhibitor which is potential for treatment of renal cell carcinoma gastrointestinal stromal tumours pancreatic cancer and nasopharyngeal carcinoma |
| CSN16610 | ENMD-2076 Tartrate | 1453868-32-0 | ENMD-2076 tartrate has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 186 nM 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2KDR and VEGFR3 FGFR1 and FGFR2 and PDGFR |
| CSN18598 | ENMD-2076 | 934353-76-1 | ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 186 nM 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2KDR and VEGFR3 FGFR1 and FGFR2 and PDGFR |
| CSN16257 | BPR1J-097 | 1327167-19-0 | BPR1J-097 is a small molecule FLT-3 inhibitor IC50117 nM with promising in vivo anti-tumour activities inhibiting FLT-3 D835Y with an IC50 of 3 nM |
| CSN21227 | Gilteritinib Hemifumarate | 1254053-84-3 | |
| CSN22654 | 5'-Fluoroindirubinoxime | 861214-33-7 | |
| CSN22754 | CHMFL-FLT3-122 | 1839150-56-9 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
